Autolus Therapeutics plc
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AUTOLUS THERAPEUTICS PLC | ||
| Date: March 20, 2025 | By: | /s/ Christian Itin, Ph.D. |
|---|---|---|
| Christian Itin, Ph.D. | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
We, the undersigned officers and directors of Autolus Therapeutics plc, hereby severally constitute and appoint Christian Itin and Robert Dolski our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Christian Itin, Ph.D. | Chief Executive Officer and Director | March 20, 2025 |
| Christian Itin, Ph.D. | (Principal Executive Officer) | |
| /s/ Robert Dolski | Chief Financial Officer | March 20, 2025 |
| Robert Dolski | (Principal Financial Officer) | |
| /s/ Andrew Mercieca | Vice President, Finance | March 20, 2025 |
| Andrew Mercieca | (Principal Accounting Officer) | |
| /s/ Michael Bonney | Chairman of the Board of Directors | March 20, 2025 |
| Michael Bonney | ||
| /s/ Joseph Anderson, Ph.D. | Director | March 20, 2025 |
| Joseph Anderson, Ph.D. | ||
| /s/ Robert Azelby | Director | March 20, 2025 |
| Robert Azelby | ||
| /s/ Linda Bain | Director | March 20, 2025 |
| Linda Bain | ||
| /s/ John Berriman | Director | March 20, 2025 |
| John Berriman | ||
| /s/ Cynthia Butitta | Director | March 20, 2025 |
| Cynthia Butitta | ||
| /s/ Robert Iannone, M.D., M.S.C.E. | Director | March 20, 2025 |
| Robert Iannone, M.D., M.S.C.E | ||
| /s/ Elisabeth Leiderman, M.D. | Director | March 20, 2025 |
| Elisabeth Leiderman, M.D. | ||
| /s/ Martin Murphy, Ph.D. | Director | March 20, 2025 |
| Martin Murphy, Ph.D. | ||
| /s/ Ravi Rao, M.D. | Director | March 20, 2025 |
| Ravi Rao | ||
| /s/ William Young, Ph.D. | Director | March 20, 2025 |
| William Young, Ph.D. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 01438) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-7 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.